澳大利亚治疗商品管理局（TGA）向联邦法院起诉Better Leaf Pty Ltd、Better Life Pty Ltd两家公司及其前董事Jack Weisberg，指控他们违反《治疗商品法》进行非法医疗广告[1]。TGA表示，这两家公司在网站、社交媒体和宣传册上虚假宣称其医用大麻产品获得TGA批准或推荐，以及获得医疗从业者背书[1]。
根据起诉文件，涉事公司在2022年11月11日至2025年5月21日期间，声称产品可治疗精神疾病、肿瘤疾病、自闭症、慢性疼痛、失眠、子宫内膜异位症和化疗恶心等多种疾病[1]。TGA指出，在多次警告和罚款通知未被理睬后，才决定向法院提起诉讼[1]。该机构警告，医用大麻的安全性、质量和有效性尚未经广泛研究和临床试验，虚假宣传可能导致使用者延迟或避免常规治疗，造成不良后果[1]。
Australia's Therapeutic Goods Administration (TGA) has taken legal action against two cannabis companies, Better Leaf Pty Ltd and Better Life Pty Ltd, along with their former director Jack Weisberg, for allegedly breaching the Therapeutic Goods Act through unlawful medical advertising [1]. The regulator filed the case in Federal Court after the companies reportedly ignored multiple warnings and penalty notices [1].
The companies are accused of making false claims on their websites, social media platforms, and promotional materials, falsely suggesting their products had been approved or recommended by the TGA and endorsed by medical practitioners [1]. According to the allegations, they promoted their cannabis products as treatments for a range of conditions including mental illness, tumors, autism, chronic pain, insomnia, endometriosis, and chemotherapy-induced nausea, spanning from November 11, 2022 to May 21, 2025 [1].
The TGA has characterized these false advertisements as posing a public health risk, noting that the safety, quality, and effectiveness of medical cannabis have not undergone extensive research and clinical trials [1]. The regulator expressed concern that consumers relying on such claims might delay or forgo conventional treatments, potentially leading to adverse health outcomes [1].